XBI

SPDR S&P Biotech ETF
*Unless otherwise stated, data provided by FactSet.

XBI Fund Description

XBI tracks an equal-weighted index of US biotechnology stocks.

XBI Factset Analytics Insight

XBI provides exposure to US biotech stocks, as defined by GICS, from a universe that invests across the market-cap spectrum. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market-cap is much smaller than some competitors. Unlike other funds in this segment, XBI is a pure biotech play, with relatively small pharma overlap. The index is rebalanced quarterly.

XBI MSCI ESG Analytics Insight

SPDR S&P Biotech ETF has an MSCI ESG Fund Rating of BB based on a score of 3.50 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. SPDR S&P Biotech ETF ranks in the 7th percentile within its peer group and in the 19th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.

PERFORMANCE [as of 09/17/21] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
XBI 7.56% -1.94% -6.92% 14.01% 11.09% 15.34% 20.36%
XBI (NAV) 7.48% -0.96% -5.51% 15.86% 12.31% 15.68% 20.53%
S&P Biotechnology Select Industry Index 7.48% -0.93% -5.43% 15.89% 12.37% 15.71% 20.33%
Thomson Reuters US Biotechnology & Medical Research -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

XBI Summary Data

SPDR
01/31/06
Open-Ended Fund
0.35%
$6.78B
$595.79M
0.02%

XBI Portfolio Data

$8.81B
-11.74
4.94
0.23%
09/20/21
196

XBI Index Data

Equal
Market Cap
Thomson Reuters US Biotechnology & Medical Research

XBI Portfolio Management

0.35%
0.07%
0.15%
-0.06%

XBI Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

XBI Fund Structure

Open-Ended Fund
No
Yes
-- / --
N/A
N/A
Low
Daily

XBI Factset Analytics Block Liquidity

As of 09/20/21
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of XBI. XBI is rated a 5 out of 5.

XBI Tradability

4,673,102
$595.79M
4,491,029
$579.31M
0.02%
$0.03
0.02%
0.23% / -0.25%
None
96.00%
25,000
179.64
0.01%
0.13%
588,109
$133.01
5

XBI Sector/Industry Breakdown


XBI
Segment Benchmark
46.86%
42.17%
29.47%
46.79%
7.37%
0.23%
6.88%
--
3.37%
5.72%
2.03%
--
0.30%
0.14%
0.26%
--

XBI Top 10 Holdings[View All]

1.28%
Veracyte Inc 0.91%
10.81%

XBI Countries


XBI
Segment Benchmark
100.00%
100.00%

XBI Regions


XBI
Segment Benchmark
100.00%
100.00%

XBI Economic Development


XBI
Segment Benchmark
100.00%
100.00%

XBI Performance Statistics

0.85
1.26
1.30
1.16
0.87%
Thomson Reuters US Biotechnology & Medical Research

XBI MSCI ESG Ratings

3.50 / 10
18.98
6.71
--
13.39%
25.64

XBI Benchmark Comparison Holdings

196
261
162
35.67%

XBI Benchmark Comparison Summary


XBI
Segment Benchmark
196
261
$8.81B
$43.30B
-11.74
-58.34
4.94
6.44
0.08%
0.39%
Low
High

XBI Benchmark Comparison Market Cap Size


XBI
Segment Benchmark
9.89%
58.24%
29.94%
25.73%
51.35%
13.19%
8.80%
2.85%